Literature DB >> 23958716

Effect of rituximab in MCNS: a role for IL-13 suppression?

Ji Eun Kim, Se Jin Park, Tae-Sun Ha, Jae Il Shin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23958716     DOI： 10.1038/nrneph.2012.289-c1

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  5 in total

1.  New drug targets in atopic dermatitis.

Authors:  Dagmar Simon; Hans-Uwe Simon
Journal:  Chem Immunol Allergy       Date:  2012-03-13

2.  Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse.

Authors:  H K Yap; W Cheung; B Murugasu; S K Sim; C C Seah; S C Jordan
Journal:  J Am Soc Nephrol       Date:  1999-03       Impact factor: 10.121

Review 3.  Rituximab therapy in nephrotic syndrome: implications for patients' management.

Authors:  Aditi Sinha; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2013-01-22       Impact factor: 28.314

4.  Atopy, serum IgE, and interleukin-13 in steroid-responsive nephrotic syndrome.

Authors:  Wai Cheung; Chang-Li Wei; Ching-Ching Seah; Stanley C Jordan; Hui-Kim Yap
Journal:  Pediatr Nephrol       Date:  2004-04-03       Impact factor: 3.714

5.  Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats.

Authors:  Kin-Wai Lai; Chang-Li Wei; Li-Kiang Tan; Puay-Hoon Tan; Gilbert S C Chiang; Caroline G L Lee; Stanley C Jordan; Hui-Kim Yap
Journal:  J Am Soc Nephrol       Date:  2007-04-11       Impact factor: 10.121
  5 in total
  3 in total

Review 1.  Pathogenesis of minimal change nephrotic syndrome: an immunological concept.

Authors:  Seong Heon Kim; Se Jin Park; Kyoung Hee Han; Andreas Kronbichler; Moin A Saleem; Jun Oh; Beom Jin Lim; Jae Il Shin
Journal:  Korean J Pediatr       Date:  2016-05-31

Review 2.  Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.

Authors:  Nima Madanchi; Martin Bitzan; Tomoko Takano
Journal:  Can J Kidney Health Dis       Date:  2017-03-13

3.  Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome.

Authors:  Roberta Fenoglio; Savino Sciascia; Giulietta Beltrame; Paola Mesiano; Michela Ferro; Giacomo Quattrocchio; Elisa Menegatti; Dario Roccatello
Journal:  Oncotarget       Date:  2018-06-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.